Table 1 Patient demographics and clinical characteristics
From: Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma
Patient’s Characteristics | Total | Primary cohort | Prospective validation cohort | p value |
|---|---|---|---|---|
(n = 881) | (n = 661) | (n = 220) | ||
Patient background | ||||
 Age, yr | 54.5 ± 10.0 | 54.4 ± 10.0 | 54.7 ± 9.9 | 0.746 |
 Gender (Male/Female) | 737/144 (83.7%/16.3%) | 551/110 (83.4%/16.6%) | 186/34 (84.6%/15.4%) | 0.680 |
 Family history of HCC (Yes/No) | 115/766 (13.0%/87.0%) | 85/576 (12.9%/87.1%) | 30/190 (13.6%/86.4%) | 0.767 |
 History of smoking (Yes/No) | 342/539 (38.8%/61.2%) | 254/407 (38.4%/61.6) | 88/132 (40.0%/60.0%) | 0.678 |
 History of alcohol use (Yes/No) | 344/537 (39.0%/61.0%) | 262/399 (39.6%/60.4%) | 82/138 (37.3%/62.7%) | 0.534 |
 Cirrhosis (Yes/No) | 720/161 (81.7%/18.3%) | 536/125 (81.1%/18.9%) | 184/36 (83.6%/16.4%) | 0.397 |
Cause of HCC | ||||
 Hepatitis B (Yes/No) | 780/101 (88.5%/11.5%) | 582/79 (88.0%/12.0%) | 198/22 (90.0%/10.0%) | 0.431 |
 Hepatitis C (Yes/No) | 69/812 (7.8%/92.2%) | 52/609 (7.9%/92.1%) | 17/203 (7.7%/92.3%) | 0.947 |
 Alcohol Liver (Yes/No) | 121/760 (13.7%/86.3%) | 94/567 (14.2%/85.8%) | 27/193 (12.3%/87.7%) | 0.467 |
 other cause (Yes/No) | 3/878 (0.3%/99.7%) | 3/658 (0.4%/99.6%) | 0/220 (0.0%/100.0%) | 0.578 |
Laboratory data | ||||
 ALT, IU/L | 36.5 (24.8,59.4) | 36.4 (24.8,60.1) | 36.5 (24.7,57.6) | 0.972 |
 AST, IU/L | 45.3 (29.8,74.2) | 45.6 (29.4,75.7) | 42.7 (30.0,69.9) | 0.450 |
 TBIL, μmol/L | 20.2 (13.5,31.1) | 21.0 (14.2,33.4) | 17.3 (12.5,25.8) | <0.001 |
 ALB, g/L | 36.6 ± 6.9 | 36.4 ± 7.2 | 37.1 ± 6.2 | 0.165 |
 ALP, IU/L | 123.9 ± 82.0 | 124.9 ± 82.3 | 121.0 ± 81.1 | 0.552 |
 GGT, IU/L | 64.3 (30.8,138.3) | 60.6 (29.9,133.7) | 71.5 (37.1,143.9) | 0.042 |
 WBC, 109/L | 4.7 ± 1.9 | 4.6 ± 1.9 | 4.8 ± 2.0 | 0.269 |
 NC, 109/L | 2.9 ± 1.5 | 2.9 ± 1.5 | 3.0 ± 1.5 | 0.554 |
 LC, 109/L | 1.23 ± 0.61 | 1.20 ± 0.61 | 1.30 ± 0.59 | 0.042 |
 PLT, 109/L | 112.3 ± 67.9 | 109.2 ± 64.5 | 121.5 ± 76.8 | 0.034 |
 NLR | 2.9 ± 2.0 | 2.9 ± 2.0 | 2.7 ± 1.8 | 0.255 |
 Cr, μmoI/L | 70.5 ± 31.9 | 71.7 ± 35.2 | 66.8 ± 18.3 | 0.008 |
 PTA, % | 75.7 ± 18.6 | 74.8 ± 18.8 | 78.4 ± 17.4 | 0.012 |
 INR | 1.2 ± 1.6 | 1.2 ± 1.8 | 1.2 ± 0.3 | 0.453 |
 AFP, ng/mL (<400/ ≥ 400) | 221/660 (25.1%/74.9%) | 161/500 (24.4%/75.6%) | 60/160 (27.3%/72.7%) | 0.388 |
Tumor-related indicators | ||||
 Tumor number (<3/ ≥ 3) | 310/556 (35.8%/64.2%) | 220/432 (33.7%/66.3%) | 90/124 (42.1%/57.9%) | 0.028 |
 Tumor size,cm (<5/ ≥ 5) | 262,537 (32.8%/67.2%) | 192/415 (31.6%/68.4%) | 70/122 (36.5%/63.5%) | 0.214 |
 Lymph node metastasis (Yes/No) | 79/802 (9.0%/91.0%) | 54/607 (8.2%/91.8%) | 25/195 (11.4%/88.6%) | 0.151 |
 Portal vein involvement (Yes/No) | 227/654 (25.8%/74.2%) | 164/497 (24.8%/75.2%) | 63/157 (28.6%/71.4%) | 0.261 |